Cargando…
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
BACKGROUND: Subcutaneous administration of Ig (SCIg) has gained popularity as an alternative route of administration but has never been rigorously examined in chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS/DESIGN: The primary objective of the PATH study (Polyneuropathy and Treatme...
Autores principales: | van Schaik, Ivo N., van Geloven, Nan, Bril, Vera, Hartung, Hans-Peter, Lewis, Richard A., Sobue, Gen, Lawo, John-Philip, Mielke, Orell, Cornblath, David R., Merkies, Ingemar S. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960813/ https://www.ncbi.nlm.nih.gov/pubmed/27455854 http://dx.doi.org/10.1186/s13063-016-1466-2 |
Ejemplares similares
-
Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Merkies, Ingemar S. J., et al.
Publicado: (2022) -
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019) -
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
por: van Schaik, Ivo N., et al.
Publicado: (2019) -
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review
por: Lewis, Richard A., et al.
Publicado: (2020) -
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)